Metastatic Melanoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

DelveInsight's, "Metastatic Melanoma Pipeline Insight 2024" report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Metastatic Melanoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Metastatic Melanoma research. Learn more about our innovative pipeline today! @ Metastatic Melanoma Pipeline Outlook [https://www.delveinsight.com/sample-request/metastatic-melanoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Metastatic Melanoma Pipeline Report

* In October 2024:- Bristol-Myers Squibb- The purpose of this study is to demonstrate that the study drug exposure level of the nivolumab + relatlimab FDC subcutaneous (SC) formulation is not worse than nivolumab + relatlimab FDC intravenous (IV) administration in participants with previously untreated metastatic or unresectable melanoma.
* In October 2024:- Regeneron Pharmaceuticals- This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called "study drugs". The study is focused on patients with a type of skin cancer known as melanoma. The aim of the study is to see how safe and effective the combination of fianlimab and cemiplimab is in treating melanoma, in comparison with the combination of two medications, relatlimab and nivolumab, commercialized under the brand name Opdualag Trademark and approved for the treatment of melanoma in adults and children.
* In October 2024:- Amgen- A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared With OPDIVO Registered (Nivolumab) in Subjects With Treatment-Naive Unresectable or Metastatic Melanoma. The purpose of this study is to assess the efficacy, safety, and immunogenicity of ABP 206 compared with Nivolumab in Subjects with Treatment-Naive Unresectable or Metastatic Melanoma.
* In October 2024;- Merck Sharp & Dohme LLC- A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02D. The goal of substudy 02D is to evaluate the safety and efficacy of investigational treatment arms in programmed cell-death 1 (PD-1) naive or PD-1 exposed participants with melanoma brain metastasis (MBM) and to identify the investigational agent(s) that, when used in combination, are superior to the current treatment options/historical control available.
* In October 2024;- Perspective Therapeutics- A Phase I/IIa, First-In-Human, Multi-Center, Monotherapy and Combination-Therapy With Nivolumab, Dose-Escalation and Dose-Expansion Study of [212Pb]VMT01 Melanocortin-1 Receptor-Targeted, Image-Guided Alpha-Particle Therapy in Subjects With Previously Treated Unresectable or Metastatic Melanoma.
* In October 2024:- Georgiamune Inc- A Phase 1/2, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of GIM-531 as a Single Agent and in Combination With Anti-PD-1 in Advanced Solid Tumors. GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy. GIM-531 exhibits its primary effect through selective inhibition of regulatory T-cells (Tregs).
* In October 2024:- IDEAYA Biosciences- This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).
* In October 2024:- Iovance Biotherapeutics, Inc.- This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who subsequently have a blinded independent central review- verified confirmed progressive disease (PD) will be offered lifileucel monotherapy in an optional crossover period.
* DelveInsight's Metastatic Melanoma pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Metastatic Melanoma treatment.
* The leading Metastatic Melanoma Companies such as Evaxion Biotech, InxMed, AiVita Biomedical, Iovance Biotherapeutics, Viralytics, Merck & Co., Neon Therapeutics, BioNTech, Bristol-Myers Squibb, Ono Pharmaceuticals, Cytovation AS, and others.
* Promising Metastatic Melanoma Therapies such as CA-4948, Pembrolizumab, BCD-217, BCD-100, Ipilimumab, Nivolumab, Dabrafenib, Trametinib, DYP688 , and others.

Stay informed about the cutting-edge advancements in Metastatic Melanoma treatments. Download for updates and be a part of the revolution in cancer care @ Metastatic Melanoma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/metastatic-melanoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Metastatic Melanoma Emerging Drugs Profile

* EVX 01: Evaxion Biotech

EVX-01, is a novel personalized cancer immunotherapy based on Evaxion's proprietary PIONEER Trademark AI technology. EVX-01 is safe and has encouraging early indications of clinically and meaningful antitumor activity. Data showed EVX-01 is capable of eliciting T-cell responses in a clinical setting where the patients received concurrent standard immune therapy, i.e. anti-PD-1 treatment. Results demonstrated an antitumor effect in combination with anti-PD-1 treatment. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Metastatic Melanoma.

* IN 10018: InxMed

IN10018 is a potent and highly selective adenosine triphosphate competitive FAK inhibitor, and InxMed has its exclusive global development and commercial operation rights. Early clinical data on IN10018 showed its safety and efficacy in multiple tumor types, and the latest research results and preclinical data demonstrated that IN10018 can also be effective in combination therapies. It is expected to overcome the tumor-associated fibrosis barrier and improve local immunity, and therefore has the potential to act as an important anchor molecule in synergy with different therapeutic modalities including immunotherapy, chemotherapy, and targeted therapy. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Metastatic Melanoma.

* AV MEL 1: AiVita Biomedical

AV MEL 1, is an investigational drug being developed by AiVita Biomedical. AIVITA has received IND approval to begin a Phase 1B trial investigating its cancer vaccine in patients with metastatic melanoma plus checkpoint inhibitors.

Learn more about Metastatic Melanoma Drugs opportunities in our groundbreaking Metastatic Melanoma Research and development projects @ Metastatic Melanoma Unmet Needs [https://www.delveinsight.com/sample-request/metastatic-melanoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Metastatic Melanoma Companies

Evaxion Biotech, InxMed, AiVita Biomedical, Iovance Biotherapeutics, Viralytics, Merck & Co., Neon Therapeutics, BioNTech, Bristol-Myers Squibb, Ono Pharmaceuticals, Cytovation AS, and others.

Metastatic Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal

Metastatic Melanoma Products have been categorized under various Molecule types such as

* Oligonucleotide
* Peptide
* Small molecule

Discover the latest advancements in Metastatic Melanoma Treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Metastatic Melanoma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/metastatic-melanoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Metastatic Melanoma Pipeline Report

* Coverage- Global
* Metastatic Melanoma Companies- Evaxion Biotech, InxMed, AiVita Biomedical, Iovance Biotherapeutics, Viralytics, Merck & Co., Neon Therapeutics, BioNTech, Bristol-Myers Squibb, Ono Pharmaceuticals, Cytovation AS, and others.
* Metastatic Melanoma Therapies- CA-4948, Pembrolizumab, BCD-217, BCD-100, Ipilimumab, Nivolumab, Dabrafenib, Trametinib, DYP688, and others.
* Metastatic Melanoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Metastatic Melanoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Metastatic Melanoma Pipeline on our website @ Metastatic Melanoma Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/metastatic-melanoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Metastatic Melanoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Metastatic Melanoma- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug name : Company name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* EVX 01: Evaxion Biotech
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* IN 10018: InxMed
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name : Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Metastatic Melanoma Key Companies
* Metastatic Melanoma Key Products
* Metastatic Melanoma- Unmet Needs
* Metastatic Melanoma- Market Drivers and Barriers
* Metastatic Melanoma- Future Perspectives and Conclusion
* Metastatic Melanoma Analyst Views
* Metastatic Melanoma Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=metastatic-melanoma-pipeline-therapeutics-assessment-companies-products-unmet-needs-market-drivers-and-barriers]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.